Migraine headaches hit hard…. Ergomar® fights back.

Ergomar® Sublingual Tablets 2 mg (ergotamine tartrate tablets, USP) is indicated as therapy to abort or prevent vascular headache, e.g., migraine and migraine variants.

Ergotamine tartrate has a well-established record of success in treating those who suffer migraine attacks. In fact, when taken in sublingual form and at the onset of an attack, ergotamine tartrate has been reported to be effective in relieving the pain of migraine in more than 70% of the cases.

Over 20 million Americans regularly experience migraine headaches. To achieve a high rate of success in treating this disorder, rapid action -- both by the patient and their medication -- is crucial. Numerous studies have shown that the sooner treatment is initiated following the onset of symptoms, the more favorable the outcome. But prompt patient action is only half the treatment equation -- in addition, the drug chosen must be rapidly available at its site of activity and, at the same time, convenient to administer.

Ergomar® meets these requirements. Because Ergomar® is formulated as a sublingual tablet, absorption of its active ingredient, ergotamine, into the bloodstream, begins soon after the tablet is placed under the tongue. In other words, Ergomar®'s absorption is not delayed, as is in the case with anti-migraine drugs that are swallowed (including even fast-dissolving tablets), since the swallowed drug must pass through the stomach and into the small intestine before absorption of the active substance begins. And Ergomar® is packaged in individual foil pouches making it easier and more convenient for the patient to carry and take at the early stage of a migraine attack.

In general, therapy with Ergomar® is well tolerated. The most common side effects include nausea and vomiting, weakness of the legs and pain in leg muscles. Ergomar® should not be taken by patients who are also taking potent CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics, or by patients with peripheral vascular disease, coronary heart disease, hypertension, impaired hepatic or renal function, severe pruritis and sepsis, or by women who are, or may become pregnant. Long-term use may increase the risk of drug dependence and chronic daily administration may lead to fibrotic complications.

We are confident that you will find Ergomar® an excellent and cost effective migraine therapy option. If you have any additional questions concerning Ergomar®, please call us toll free at 1-800-247-4896.

Please see Full Prescribing Information for important safety information including Boxed Warning.

• Package Insert
• New Customer Account Form